The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.
- Analysis: Kymab’s ‘patent bargain’ clarification and why it matters 25-06-2020
- SPCs: a deep dive into CJEU case law 23-06-2020
- Lanham Act: brand owners’ current weapon of choice 11-06-2020
- Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020
- Royalty Pharma: welcome clarity mixed with unwelcome ambiguity 15-05-2020
US medical technology company CardioNet has lost an appeal at the US Court of Appeals for the Federal Circuit , which found its patents covered abstract concepts and therefore are invalid.